PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q1 2024 Earnings Call Transcript

Reza Zadno: Yeah, thanks. As far as the opportunity for cancer, there are millions of men in the US who are on the sidelines and opting for, they’re basically washable waiters for us, it’s early to assess that market. That’s why we are starting to conduct clinical studies. And where we see the benefit of our technology is, again, I start with the safety profile because we are, if we can replicate the same safety profile as we had in our Water study that is a great plus to what the current treatments are on Friday this will be discussed in more detail. Hopefully, you can attend and see that. And the second part of the question, could you?

Mike Kratky: Just on the timelines for the ongoing clinical trial?

Reza Zadno: Yeah. So, the second for your, we are conducting the PRCT-001 and 002. One is a hundred patients. The other one is 20 patients, one with BPH and cancer. The other one doesn’t. Patients do not need necessarily to have BPH. So once we finish those studies, then we are going to move into another timeline. But at this point we are not talking about the nature of that study. But the whole goal similar to BPH, is to generate enough data because we want to lead with clinical data when we enter this market.

Mike Kratky: Got it. Thanks very much.

Operator: And I’m not showing any further questions. I’d like to turn the call back over to Reza Zadno our CEO, for any closing remarks.

Reza Zadno: Yeah, thanks everyone for attending this call. We look forward to seeing many of you hopefully at the AUA Investor event on May 3rd. And thanks again and see you soon.

Operator: Ladies and gentlemen, that concludes today’s presentation. You may now disconnect and have a wonderful day.